Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 236

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 236
---
 |     |          $1.41 |
| Risk-free interest rate                            |     |  4.13% – 4.18% |
| Expected volatility                                |     | 88.29% –91.46% |
| Expected term (in years)                           |     |    4.99 – 5.59 |
| Expected dividend yield                            |     |             0% |

The Company determines the assumptions used in the option pricing model in the following manner: Risk-Free Interest Rate –For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. Expected Volatility– Due to the Company’s limited historical stock price volatility data, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its share-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. - 161 -

Expected Dividend– The expected dividend yield is assumed to be zero because the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. Expected Term– The Company estimates the expected term of its stock options granted to employees and non-employeedirectors using the simplified method, whereby, the expected term equals the average of the vesting term and the original.

| (2) | These amount reported in the Stock Awards column represents the grant date fair value of restricted stock units                                                                                                                                          
 granted to the named executive officer as of the grant date as computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, not including any estimates of forfeitures. The value of a restricted stock 
 unit is equal to the Company’s stock price on the date of grant.                                                                                                                                                                                         |

| (3) | Amount represents cash bonus earned for performance in 2023 based upon achievement of corporate performance                                                                       
 goals. Amounts payable in respect of 2024 under our 2024 Bonus Plan, if any, are not yet determinable and are expected to be determined in the first